José Luis Miguel-Carrasco

José Luis Miguel-Carrasco

Auto-generated profile, based on publicly available information

José Luis Miguel-Carrasco

Departamento de Fisiología, Facultad de Farmacia, Universidad de Sevilla , Sevilla , Spain

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2010 in Journal of Inflammation
Verified
Journal Article
Open access
PDF file
JMJosé L Miguel-Carrasco
José L Miguel-Carrasco
SZSonia Zambrano
Sonia Zambrano
ABAntonio J Blanca
Antonio J Blanca
Alfonso MateAlfonso Mate
Alfonso Mate
CARMEN VAZQUEZCARMEN VAZQUEZ
CARMEN VAZQUEZ
Background: Captopril is an angiotensin-converting enzyme (ACE) inhibitor widely used in the treatment of arterial hypertension and cardiovascular diseases. Our objective was to study whether captopril is able to attenuate the cardiac inflammatory process associated with arterial hypertension.Methods: Left ventricle mRNA expression and plasma levels of pro-inflammatory (interleukin-1β (IL-1β) and IL-6) and anti-inflammatory (IL-10) cytokines, were measured in spontaneously hypertensive rats (SHR) and their control normotensive, Wistar-Kyoto (WKY) rats, with or without a 12-week treatment with captopril (80 mg/Kg/day; n = six animals per group). To understand the mechanisms involved in the effect of captopril, mRNA expression of ACE, angiotensin II type I receptor (AT1R) and p22phox (a subunit of NADPH oxidase), as well as NF-κB activation and expression, were measured in the left ventricle of these animals.Results: In SHR, the observed increases in blood pressures, heart rate, left ventricle relative weight, plasma levels and cardiac mRNA expression of IL-1β and IL-6, as well as the reductions in the plasma levels and in the cardiac mRNA expression of IL-10, were reversed after the treatment with captopril. Moreover, the mRNA expressions of ACE, AT1R and p22phox, which were enhanced in the left ventricle of SHR, were reduced to normal values after captopril treatment. Finally, SHR presented an elevated cardiac mRNA expression and activation of the transcription nuclear factor, NF-κB, accompanied by a reduced expression of its inhibitor, IκB; captopril administration corrected the observed changes in all these parameters.Conclusion: These findings show that captopril decreases the inflammation process in the left ventricle of hypertensive rats and suggest that NF-κB-driven inflammatory reactivity might be responsible for this effect through an inactivation of NF-κB-dependent pro-inflammatory factors.

1 November 2008 in American Journal of Hypertension
Verified
Journal Article
Open access
PDF file
JMJose L. Miguel-Carrasco
Jose L. Miguel-Carrasco
Alfonso MateAlfonso Mate
Alfonso Mate
MMMaria T. Monserrat
Maria T. Monserrat
JAJose L. Arias
Jose L. Arias
OAOscar Aramburu
Oscar Aramburu
CARMEN VAZQUEZCARMEN VAZQUEZ
CARMEN VAZQUEZ
Background. The mechanism(s) underlying the effects of L-carnitine (β-hydroxy-γ-N-trimethylammonium-butyrate; LC) in cardiovascular diseases are not we

1 April 2010 in European Journal of Pharmacology
Verified
Journal Article
Closed access
JMJosé L. Miguel-Carrasco
José L. Miguel-Carrasco
MMMaría T. Monserrat
María T. Monserrat
Alfonso MateAlfonso Mate
Alfonso Mate
CARMEN VAZQUEZCARMEN VAZQUEZ
CARMEN VAZQUEZ

11 January 2014 in American Journal of Hypertension
Verified
Journal Article
Open access
PDF file
SZSonia Zambrano
Sonia Zambrano
ABAntonio J. Blanca
Antonio J. Blanca
MRMaría V. Ruiz-Armenta
María V. Ruiz-Armenta
JMJosé L. Miguel-Carrasco
José L. Miguel-Carrasco
MAMiguel Arévalo
Miguel Arévalo
CARMEN VAZQUEZCARMEN VAZQUEZ
CARMEN VAZQUEZ
The development of renal fibrosis is a consequence of arterial hypertension. L-carnitine plays an essential role in the β-oxidation of fatty acids, and we have previously demonstrated hypotensive, antioxidant, and anti-inflammatory effects of L-carnitine in arterial hypertension. This work aims to analyze the effect of L-carnitine on renal fibrosis and to explore the participation of peroxisome-proliferator activated receptor (PPAR)–γ in this effect. Four groups or rats were used: control, treated with L-carnitine, treated with L-NAME, and treated with L-carnitine + L-NAME. Cultured rat kidney cells were also used to examine the role of PPAR-γ in L-carnitine effect. An increase in the expression of collagen, transforming growth factor beta 1 (TGF-β1), connective tissue growth factor (CTGF), Nox2, and Nox4 was found in the kidney of L-NAME–treated rats. Hypertensive rats presented with an expansion of renal fibrotic areas, which was also accompanied by overexpression of proinflammatory cytokines, interleukin (IL)–1β, and IL-6. A reduction in the expression of PPAR-γ and in that of anti-inflammatory IL-10 was found in the kidney of these rats. Simultaneous treatment with L-carnitine attenuated the renal fibrosis (which correlated with a reduction of plasma TGF-β1 levels) and the pro-oxidative and proinflammatory status reported in L-NAME groups, with a concomitant increase in the expression of PPAR-γ. Furthermore, the antifibrotic effect of L-carnitine could be blocked by PPAR-γ inhibition. This study confirms the efficacy of L-carnitine against hypertension-associated renal fibrosis from in vivo and in vitro studies and suggests that the L-carnitine effect occurs in a PPAR-γ–dependent manner.

1 April 2013 in Biochemical Pharmacology
Verified
Journal Article
Closed access
SZSonia Zambrano
Sonia Zambrano
ABAntonio J. Blanca
Antonio J. Blanca
MRMaría V. Ruiz-Armenta
María V. Ruiz-Armenta
JMJosé L. Miguel-Carrasco
José L. Miguel-Carrasco
MAMiguel Arévalo
Miguel Arévalo
CARMEN VAZQUEZCARMEN VAZQUEZ
CARMEN VAZQUEZ

1 August 2007 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
LGLucía Gómez-Amores
Lucía Gómez-Amores
Alfonso MateAlfonso Mate
Alfonso Mate
JMJosé L. Miguel-Carrasco
José L. Miguel-Carrasco
LJLuís Jiménez
Luís Jiménez
Angeles  JosAngeles Jos
Angeles Jos
CARMEN VAZQUEZCARMEN VAZQUEZ
CARMEN VAZQUEZ